Purpose: The majority of patients with
prostate cancer who are treated with
androgen-deprivation
therapy (ADT) will eventually develop fatal metastatic
castration-resistant
prostate cancer (mCRPC). Currently, there are no effective durable
therapies for patients with mCRPC. High expression of
galectin-1 (Gal-1) is associated with
prostate cancer progression and poor clinical outcome. The role of
Gal-1 in
tumor progression is largely unknown. Here, we characterized
Gal-1 functions and evaluated the
therapeutic effects of a newly developed
Gal-1 inhibitor, LLS30, in mCRPC.Experimental Design: Cell viability, colony formation, migration, and invasion assays were performed to examine the effects of inhibition of
Gal-1 in CRPC cells. We used two human CRPC xenograft models to assess growth-inhibitory effects of LLS30. Genome-wide gene expression analysis was conducted to elucidate the effects of LLS30 on metastatic PC3 cells.Results:
Gal-1 was highly expressed in CRPC cells, but not in
androgen-sensitive cells.
Gal-1 knockdown significantly inhibited CRPC cells' growth, anchorage-independent growth, migration, and invasion through the suppression of
androgen receptor (AR) and Akt signaling. LLS30 targets
Gal-1 as an allosteric inhibitor and decreases Gal-1-binding affinity to its binding partners. LLS30 showed in vivo efficacy in both AR-positive and AR-negative xenograft models. LLS30 not only can potentiate the antitumor effect of
docetaxel to cause complete regression of
tumors, but can also effectively inhibit the invasion and
metastasis of
prostate cancer cells in vivoConclusions: Our study provides evidence that
Gal-1 is an important target for mCRPC
therapy, and LLS30 is a promising small-molecule compound that can potentially overcome mCRPC. Clin
Cancer Res; 24(17); 4319-31. ©2018 AACR.